These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19032830)

  • 1. Serum soluble CD30 in early arthritis: a sign of inflammation but not a predictor of outcome.
    Savolainen E; Matinlauri I; Kautiainen H; Luosujärvi R; Kaipiainen-Seppänen O
    Clin Exp Rheumatol; 2008; 26(5):922-5. PubMed ID: 19032830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R; Lunardi C; Bocci EB; Bobbio-Pallavicini F; Schillaci G; Caporali R; Bistoni O; Pirro M; Pitzalis C; Montecucco C
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy.
    Gerli R; Bistoni O; Lunardi C; Giacomelli R; Tomassini C; Biagini P; Pitzalis C
    Rheumatology (Oxford); 1999 Dec; 38(12):1282-4. PubMed ID: 10587561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical prediction rule combining routine assessment and power Doppler ultrasonography for predicting progression to rheumatoid arthritis from early-onset undifferentiated arthritis.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Filippucci E; Grassi W
    Clin Exp Rheumatol; 2010; 28(5):686-94. PubMed ID: 20822707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection.
    Kamali K; Abbasi MA; Farokhi B; Abbasi A; Fallah P; Seifee MH; Ghadimi N; Rezaie AR
    Exp Clin Transplant; 2009 Dec; 7(4):237-40. PubMed ID: 20353374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: an observational cohort study.
    van Aken J; van Dongen H; le Cessie S; Allaart CF; Breedveld FC; Huizinga TW
    Ann Rheum Dis; 2006 Jan; 65(1):20-5. PubMed ID: 15901632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble CD30 levels in Behçet's disease.
    Düzgün N; Ayaslioglu E; Tutkak H
    Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S17-20. PubMed ID: 15515777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort.
    Le Loët X; Brazier M; Mejjad O; Boumier P; Daragon A; Gayet A; Pouplin S; Tron F; Zarnitsky C; Vittecoq O; Menard JF; Fardellone P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1739-47. PubMed ID: 20740612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased galectin-3 may serve as a serologic signature of pre-rheumatoid arthritis while markers of synovitis and cartilage do not differ between early undifferentiated arthritis subsets.
    Issa SF; Duer A; Østergaard M; Hørslev-Petersen K; Hetland ML; Hansen MS; Junker K; Lindegaard HM; Møller JM; Junker P
    Arthritis Res Ther; 2017 Apr; 19(1):80. PubMed ID: 28446218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.
    Nadali G; Vinante F; Stein H; Todeschini G; Tecchio C; Morosato L; Chilosi M; Menestrina F; Kinney MC; Greer JP
    J Clin Oncol; 1995 Jun; 13(6):1355-60. PubMed ID: 7751879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum soluble interleukin-2 receptor predicts early remission in patients with recent-onset rheumatoid arthritis treated with a single disease-modifying antirheumatic drug.
    Kuuliala A; Leirisalo-Repo M; Möttönen T; Hannonen P; Nissilä M; Kautiainen H; Korpela M; Julkunen H; Hakola M; Repo H;
    Clin Exp Rheumatol; 2005; 23(2):243-6. PubMed ID: 15895898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis.
    Ulusoy H; Kamanli A; Ilhan N; Kuru O; Arslan S; Alkan G; Ozgocmen S
    Rheumatol Int; 2012 Dec; 32(12):3857-62. PubMed ID: 22193227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
    Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
    Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study).
    Heimans L; Akdemir G; Boer KV; Goekoop-Ruiterman YP; Molenaar ET; van Groenendael JH; Peeters AJ; Steup-Beekman GM; Lard LR; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
    Arthritis Res Ther; 2016 Jan; 18():23. PubMed ID: 26794605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis.
    Nadali G; Vinante F; Ambrosetti A; Todeschini G; Veneri D; Zanotti R; Meneghini V; Ricetti MM; Benedetti F; Vassanelli A
    J Clin Oncol; 1994 Apr; 12(4):793-7. PubMed ID: 8151321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretransplantation soluble CD30 level as a predictor of acute rejection in kidney transplantation: a meta-analysis.
    Chen Y; Tai Q; Hong S; Kong Y; Shang Y; Liang W; Guo Z; He X
    Transplantation; 2012 Nov; 94(9):911-8. PubMed ID: 23052636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30.
    Dong W; Shunliang Y; Weizhen W; Qinghua W; Zhangxin Z; Jianming T; He W
    Transpl Immunol; 2006 Jun; 16(1):41-5. PubMed ID: 16701175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.